NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Gyre Therapeutics, Inc. GYRE
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$116.6M
▲ 10.2% vs FY2024
EPS · FY25
$0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
11.7%
Net margin · FY25
8.5%
Dividend coverage
0.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 116.6M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
8 cents of every revenue dollar became profit this year.
Per share
USD 0.02
Diluted EPS, FY2025
EPS
Dividend
Earnings covered only a fraction of the dividend — the rest came from cash or borrowing.
Profitability
11.7%
Return on equity, FY2025
ROE
Operating margin9.9%
Net margin8.5%
Return on assets6.8%
Each USD of equity produced 12 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+41.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+4.5%
+41.0%
+2.1%
Net income
+31.8%
−0.7%
EPS, diluted
−12.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 166.1M
total assets, end of FY2025
Total assetsUSD 166.1M
EquityUSD 106.0M
CashUSD 37.1M
Current ratio5.60×
Equity funds 64% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.0
0.0
·
0.0
0.0
·
·
0.0
0.0
0.1
0.1
0.1
0.0
Operating income $B
0.0
0.0
−0.1
0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
EBITDA $B
0.0
0.0
−0.1
0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
0.0
0.0
−0.0
0.0
0.0
−0.0
Net income $B
0.0
0.0
−0.1
0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
EPS, diluted $
0.02
0.05
−1.41
0.03
−2.87
−2.93
−4.60
−2.68
−7.45
−21.75
−49.99
−17.99
−27.29
−0.21
−0.27
0.36
−1.54
Dividend / sh $
·
·
·
0.24
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
1044
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
11.7
75.4
−640.4
10.3
−150.1
−77.9
−58.6
−39.9
−92.1
−71.4
·
·
·
−17.3
−6.4
13.6
−57.1
Shares out B
0.09
0.09
0.08
0.06
0.03
0.02
0.01
0.01
0.01
0.00
0.00
0.00
0.03
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed